tbuckley/cabot-search huggingface dataset:
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer
Authors: Sophie Leboulleux, Claire Bournaud, Cecile N. Chougnet, Slimane Zerdoud, Abir Al Ghuzlan, Bogdan Catargi, Christine Do Cao, Antony Kelly, Marie-Luce Barge, Ludovic Lacroix, Inna Dygai, Pierre Vera, Daniela Rusu, Olivier Schneegans, Danielle Benisvy, Marc Klein, Julie Roux, Marie-Claude Eberle, Delphine Bastie, Camila Nascimento, Anne-Laure Giraudet, Nathalie Le Moullec, Stéphane Bardet, Delphine Drui, Nathalie Roudaut, Yann Godbert, Olivier Morel, Anne Drutel, Livia Lamartina, Claire Schvartz, Fritz-Line Velayoudom, Martin-Jean Schlumberger, Laurence Leenhardt, Isabelle Borget
Journal: New England Journal of Medicine (2022)

In patients with low-risk differentiated thyroid cancer undergoing thyroidectomy, the postoperative administration of radioiodine (iodine-131) is controversial in the absence of demonstrated benefits.In this prospective, randomized, phase 3 trial, we assigned patients with low-risk differentiated thyroid cancer who were undergoing thyroidectomy to receive ablation with postoperative administration of radioiodine (1.1 GBq) after injections of recombinant human thyrotropin (radioiodine group) or to receive no postoperative radioiodine (no-radioiodine group). The primary objective was to assess whether no radioiodine therapy was noninferior to radioiodine therapy with respect to the absence of a composite end point that included functional, structural, and biologic abnormalities at 3 years. Noninferiority was defined as a between-group difference of less than 5 percentage points in the percentage of patients who did not have events that included the presence of abnormal foci of radioiodine uptake on whole-body scanning that required subsequent treatment (in the radioiodine group only), abnormal findings on neck ultrasonography, or elevated levels of thyroglobulin or thyroglobulin antibodies. Secondary end points included prognostic factors for events and molecular characterization.Among 730 patients who could be evaluated 3 years after randomization, the percentage of patients without an event was 95.6% (95% confidence interval [CI], 93.0 to 97.5) in the no-radioiodine group and 95.9% (95% CI, 93.3 to 97.7) in the radioiodine group, a difference of -0.3 percentage points (two-sided 90% CI, -2.7 to 2.2), a result that met the noninferiority criteria. Events consisted of structural or functional abnormalities in 8 patients and biologic abnormalities in 23 patients with 25 events. Events were more frequent in patients with a postoperative serum thyroglobulin level of more than 1 ng per milliliter during thyroid hormone treatment. Molecular alterations were similar in patients with or without an event. No treatment-related adverse events were reported.In patients with low-risk thyroid cancer undergoing thyroidectomy, a follow-up strategy that did not involve the use of radioiodine was noninferior to an ablation strategy with radioiodine regarding the occurrence of functional, structural, and biologic events at 3 years. (Funded by the French National Cancer Institute; ESTIMABL2 ClinicalTrials.gov number, NCT01837745.).
ASSOCIATION BETWEEN CARDIOVASCULAR COMORBIDITIES AND MORTALITY AMONGST SARSCOV-2 PATIENTS
Authors: Aaron Douen, Jeremy Jaehwan Oh, Marc Sukhoo-Pertab, Samuel Tan, Carly Bowser, Madison Lindsey, Prakash Ramdass, Ofek Hai, George Juang, Aleksandre Toreli
Journal: Journal of the American College of Cardiology (2022)
GUATEMALA’S MULTICENTER ACUTE CORONARY SYNDROME REGISTRY
Authors: Sofia Leal, Mariana Gil, Juan Carlos Santis, Josue F. Samayoa Ruano, Elisa M. Anleu de Leon, Magda I. Ramos Castro, Oscar F. Castro Alvarado, Paola Overall, Luis A. Rodriguez Cifuentes, Karla Y. Miranda Sandoval, Juan P. Pineda, Kevin O. Flores Andrade, Roberto A. Perez Reyes, Sofia W. Giron Blas
Journal: Journal of the American College of Cardiology (2022)
Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care
Authors: Yaw A Nyame, Matthew R Cooperberg, Marcus G Cumberbatch, Scott E Eggener, Ruth Etzioni, Scarlett L Gomez, Christopher Haiman, Franklin Huang, Cheryl T Lee, Mark S Litwin, Georgios Lyratzopoulos, James L Mohler, Adam B Murphy, Curtis Pettaway, Isaac J Powell, Peter Sasieni, Edward M Schaeffer, Shahrokh F Shariat, John L Gore
Journal: European Urology (2022)
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Authors: Li Chen, Yi-Zhou Jiang, Song-Yang Wu, Jiong Wu, Gen-Hong Di, Guang-Yu Liu, Ke-Da Yu, Lei Fan, Jun-Jie Li, Yi-Feng Hou, Zhen Hu, Can-Ming Chen, Xiao-Yan Huang, A-Yong Cao, Xin Hu, Shen Zhao, Xiao-Yan Ma, Ying Xu, Xiang-Jie Sun, Wen-Jun Chai, Xiaomao Guo, Xizi Chen, Yanhui Xu, Xiao-Yu Zhu, Jian-Jun Zou, Wen-Tao Yang, Zhong-Hua Wang, Zhi-Ming Shao
Journal: Clinical Cancer Research (2022)

Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. We aimed to assess the efficacy and safety of a novel combination of famitinib, camrelizumab, and nab-paclitaxel in advanced immunomodulatory TNBC.This open-label, single-arm, phase II study enrolled patients with previously untreated, advanced, immunomodulatory TNBC (CD8 IHC staining ≥10%). Eligible patients received 20 mg of oral famitinib on days 1 to 28, 200 mg of i.v. camrelizumab on days 1 and 15, and i.v. nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 in 4-week cycles. The primary endpoint was objective response rate (ORR), as assessed by investigators per RECIST v1.1. Key secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response (DOR), safety, and exploratory biomarkers.Forty-eight patients were enrolled and treated. Median follow-up was 17.0 months (range, 8.7-24.3). Confirmed ORR was 81.3% [95% confidence interval (CI), 70.2-92.3], with five complete and 34 partial responses. Median PFS was 13.6 months (95% CI, 8.4-18.8), and median DOR was 14.9 months [95% CI, not estimable (NE)-NE]. Median OS was not reached. No treatment-related deaths were reported. Among 30 patients with IHC, 13 (43.3%) were programmed death-ligand 1 (PD-L1)-negative, and PD-L1 was associated with favorable response. PKD1 and KAT6A somatic mutations were associated with therapy response.The triplet regimen was efficacious and well tolerated in previously untreated, advanced, immunomodulatory TNBC. The randomized controlled FUTURE-SUPER trial is under way to validate our findings. See related commentary by Salgado and Loi, p. 2728.
Reprogramming of fibroblasts into expandable cardiovascular progenitor cells via small molecules in xeno-free conditions
Authors: Jia Wang, Shanshan Gu, Fang Liu, Zihao Chen, He Xu, Zhun Liu, Weisheng Cheng, Linwei Wu, Tao Xu, Zhongyan Chen, Ding Chen, Xuena Chen, Fanzhu Zeng, Zhiju Zhao, Mingliang Zhang, Nan Cao
Journal: Nature Biomedical Engineering (2022)
SAFETY AND EFFICACY OF EDOXABAN MONOTHERAPY AFTER BIOABSORBABLE POLYMER EVEROLIMUS-ELUTING STENT IMPLANTATION IN A HUMAN-LIKE CORONARY ATHEROSCLEROTIC PORCINE MODEL
Authors: Daisuke Kitano, Yuxin Li, Suguru Migita, Yutaka Koyama, Akira Onishi, Daiichiro Fuchimoto, Shunichi Suzuki, Yoshiyuki Nakamura, Atsushi Hirayama, Hiroyuki Hao, Yasuo Okumura
Journal: Journal of the American College of Cardiology (2022)
ASSESSMENT OF BALLOON EXPANDABLE VS SELF EXPANDABLE TRANSCATHETER HEART VALVES FOR TAVR IN PATIENTS WITH A LOW EJECTION FRACTION
Authors: Ahmad Mustafa, Denny Wang, Arber Kodra, Chad Kliger, Luigi Pirelli, Priti Mehla, Efstathia Mihelis, Bruce Rutkin, Elana Koss, Sean R. Wilson, Gregory A. Maniatis, Mohammed Nasir Imam, Puneet Gandotra, Robert Kalimi, Azhar A. Supariwala, Perwaiz Meraj, Nirav Patel, S. Jacob Scheinerman, Craig Basman
Journal: Journal of the American College of Cardiology (2022)
PCL22-187: Functional Role of TREM2 in NASH and HCC Development
Authors: Souradipta Ganguly, Aleman Muench German, Brin Rosenthal, Naser Khader, Asra Irfan, Nathalia Castorena, Pejman Soroosh, Tatiana Kisseleva, David A Brenner, Debanjan Dhar
Journal: Journal of the National Comprehensive Cancer Network (2022)
SHOOT: phylogenetic gene search and ortholog inference
Authors: David Mark Emms, Steven Kelly
Journal: Genome biology (2022)

Abstract Determining the evolutionary relationships between genes is fundamental to comparative biological research. Here, we present SHOOT. SHOOT searches a user query sequence against a database of phylogenetic trees and returns a tree with the query sequence correctly placed within it. We show that SHOOT performs this analysis with comparable speed to a BLAST search. We demonstrate that SHOOT phylogenetic placements are as accurate as conventional tree inference, and it can identify orthologs with high accuracy. In summary, SHOOT is a fast and accurate tool for phylogenetic analyses of novel query sequences. It is available online at www.shoot.bio .
EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS AMONG MEDICARE PATIENTS WITH ATRIAL FIBRILLATION AND CANCER
Authors: Sean Chen, Anne Hellkamp, Brooke Alhanti, Chiara Melloni, Jonathan P. Piccini, Michel Georges Khouri, Christopher B. Granger, Sean Pokorney
Journal: Journal of the American College of Cardiology (2022)
CHARACTERIZATION AND TREATMENT PATTERNS OF NEWLY-DIAGNOSED PULMONARY ARTERIAL HYPERTENSION PATIENTS WITH CARDIOVASCULAR COMORBIDITIES: REAL-WORLD EVIDENCE FROM THE EXPOSURE STUDY
Authors: Maria Pilar Escribano-Subias, Sean P. Gaine, Audrey Muller, Riho Klement, Tobias Lange, Stefan Söderberg
Journal: Journal of the American College of Cardiology (2022)
Self-reported Transportation Barriers to Health Care Among US Cancer Survivors
Authors: Changchuan Jiang, K. Robin Yabroff, Lei Deng, Qian Wang, Stuthi Perimbeti, Charles L. Shapiro, Xuesong Han
Journal: JAMA Oncology (2022)

This cross-sectional study uses data from the 2014-2018 National Health Interview Survey to examine various characteristics of US cancer survivors who experience delays in care due to transportation barriers.
PLOSL: Population learning followed by one shot learning pulmonary image registration using tissue volume preserving and vesselness constraints
Authors: Di Wang, Yue Pan, Oguz C. Durumeric, Joseph M. Reinhardt, Eric A. Hoffman, Joyce D. Schroeder, Gary E. Christensen
Journal: Medical Image Analysis (2022)

This paper presents the Population Learning followed by One Shot Learning (PLOSL) pulmonary image registration method. PLOSL is a fast unsupervised learning-based framework for 3D-CT pulmonary image registration algorithm based on combining population learning (PL) and one-shot learning (OSL). The PLOSL image registration has the advantages of the PL and OSL approaches while reducing their respective drawbacks. The advantages of PLOSL include improved performance over PL, substantially reducing OSL training time and reducing the likelihood of OSL getting stuck in local minima. PLOSL pulmonary image registration uses tissue volume preserving and vesselness constraints for registration of inspiration-to-expiration and expiration-to-inspiration pulmonary CT images. A coarse-to-fine convolution encoder-decoder CNN architecture is used to register large and small shape features. During training, the sum of squared tissue volume difference (SSTVD) compensates for intensity differences between inspiration and expiration computed tomography (CT) images and the sum of squared vesselness measure difference (SSVMD) helps match the lung vessel tree. Results show that the PLOSL (SSTVD+SSVMD) algorithm achieved subvoxel landmark error while preserving pulmonary topology on the SPIROMICS data set, the public DIR-LAB COPDGene and 4DCT data sets.
8P Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer
Authors: S. Lheureux, E. Rosen, E. Lee, D. Spigel, M. Højgaard, E. Fontana, N.B. Mettu, L. Carter, S. Patel, R. Papp, S. May, P. Nejad, D. Ulanet, M. Wainszelbaum, P. Manley, M. Koehler, A.J. Fretland, R. Plummer, T.A. Yap
Journal: Annals of Oncology (2022)
Association of Level I and II Trauma Center Expansion With Insurer Payments in Texas From 2011 to 2019
Authors: Vivian Ho, Marah N. Short, Maura Coughlin, Shara McClure, James W. Suliburk
Journal: JAMA Network Open (2022)

31 189 vs $39 773) in 2019.Texas did not experience the growth in trauma fee activations or prices noted in Florida.A limited number of trauma centers in the 3 Texas metropolitan statistical areas included in this study received exceptionally high payments for visits with lower injury severity.A limitation of this study was that we analyzed claims from only 1 large insurer in 3 metropolitan statistical areas.Unlike surprise billing, 4 trauma activation fees may not require government intervention.Insurers' oversight may sufficiently limit outsize bills submitted by a few hospitals.In fact, Florida Blue recently renegotiated lower trauma rates with HCA Healthcare. 5
Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018
Authors: Müjde Durmaz, Otto Visser, Eduardus F. M. Posthuma, Rolf E. Brouwer, Djamila E. Issa, Daphne de Jong, King H. Lam, Nicole M. A. Blijlevens, Josée M. Zijlstra, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed
Journal: Blood Cancer Journal (2022)

It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to increase in an era where rituximab-containing chemotherapy reigns for almost two decades. Therefore, we evaluated trends in primary therapy and relative survival (RS) among Dutch DLBCL patients diagnosed between 1989 and 2018. Analyses were performed separately according to the stage I (N = 6952) and stage II-IV disease (N = 20,676), stratified by calendar period and age (18-64, 65-74, and ≥75 years). The use of chemotherapy ± radiotherapy increased over time across all age and stage groups. As of the mid-2000s, >95% of chemotherapy-treated patients received chemoimmunotherapy, irrespective of age and stage. Overall, RS increased significantly over time across all age groups, especially after 2003 when rituximab-containing chemotherapy had become the standard of care. However, RS increased less pronounced between 2003-2010 and 2011-2018 than between 1989-2002 and 2003-2010. These findings were congruent across all studied stage groups. Five-year RS across the three age groups during 2011-2018 was 96%, 84%, and 67% for stage I DLBCL and 75%, 60%, and 46% for stage II-IV DLBCL. Collectively, survival in DLBCL increased modestly beyond the initial introduction of rituximab, with apparent survival differences across age and stage that warrant novel treatment approaches.
DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN/VITAMIN K ANTAGONISTS FOR STROKE PREVENTION IN FRAIL PATIENTS WITH ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Akhil Jain, Priya Shenwai, Ankita Lakshmanan, Aamer Mohammad,. Neha, Bhavyasri Merugu, Neelima Gaddam, Frailyn Nunez Guzman, Vikram Itare, Jilmil Raina, Rupak Desai
Journal: Journal of the American College of Cardiology (2022)
CHARACTERISTICS OF METHAMPHETAMINE ASSOCIATED CARDIOMYOPATHY AT A TERTIARY CLINICAL CENTER IN HAWAII
Authors: Isaac Mizrahi, Parthav Shah, Zia Rehman Khan, Corey Lum, Ricky Huang, Todd Nagamine, Len N. Shimabuku, Len Shiraishi, David Lee, Len N. Shimabuku, Michael Brodsky
Journal: Journal of the American College of Cardiology (2022)
Eliminating the original cargos of glioblastoma cell-derived small extracellular vesicles for efficient drug delivery to glioblastoma with improved biosafety
Authors: Yuhang Guo, Guowen Hu, Yuguo Xia, HaiYan Li, Ji Yuan, Juntao Zhang, Yu Chen, Hua Guo, Yunlong Yang, Yang Wang, Zhifeng Deng
Journal: Bioactive Materials (2022)

Tumor derived small extracellular vesicles (TsEVs) display a great potential as efficient nanocarriers for chemotherapy because of their intrinsic targeting ability. However, the inherited risks of their original cargos (like loaded proteins or RNAs) from parent cancer cells in tumor progression severely hinder the practical application. In this study, a saponin-mediated cargo elimination strategy was established and practiced in glioblastoma (GBM) cell-derived small extracellular vesicles (GBM-sEVs). A high eliminating efficacy of the cargo molecules was confirmed by systematic analysis of the original proteins and RNAs in GBM-sEVs. In addition, the inherited functions of GBM-sEVs to promote GBM progression vanished after saponin treatment. Moreover, the results of cellular uptake analysis and in vivo imaging analysis demonstrated that saponin treatment preserved the homotypic targeting ability of GBM-sEVs. Thus, we developed an efficient nanocarrier with improved biosafety for GBM suppression. Furthermore, doxorubicin (DOX) transported by the saponin-treated GBM-sEVs (sa-GBM-sEVs) displayed an effective tumor suppression in both subcutaneous and orthotopic GBM models of mouse. Collectively, this study provides a feasible way to avoid the potential protumoral risks of TsEVs and can advance the clinical application of TsEVs in chemotherapy.
Double-band ligation-assisted endoscopic submucosal resection for type 1 gastric neuroendocrine tumor with type A gastritis
Authors: Chao Deng, Suhua Wu, Feng Xu, Lin Lv, Zhihang Zhou, Song He
Journal: Endoscopy (2022)

A 72-year-old woman was diagnosed with a 10-mm type 1 gastric neuroendocrine tumor (NET) in the gastric body, associated with type A gastritis and diabetes mellitus ([Fig. 1 a]). Endoscopic ultrasonography indicated that the lesion was confined to the submucosa. In order to resect the lesion completely with clean margins, we applied a double-band ligation-assisted endoscopic submucosal resection (dL-ESMR) technique.
Excessive Wrinkling on the Dorsum of the Hands and Wrists
Authors: Qian Zhang, Yu-Ying Huang, Jiu-Hong Li
Journal: JAMA Dermatology (2022)

A man in his 20s presented with thickening and swelling of hands, including symmetrical white and transparent papules, white keratosis, and excessive wrinkling after immersion in water, accompanied by burning pruritus for 3 years. What is your diagnosis?
Whole-genome profiling of DNA methylation and hydroxymethylation identifies distinct regulatory programs among innate lymphocytes
Authors: Vincent Peng, Xiaoyun Xing, Jennifer K Bando, Tihana Trsan, Blanda Di Luccia, Patrick L Collins, Daofeng Li, Wei-Le Wang, Hyung Joo Lee, Eugene M Oltz, Ting Wang, Marco Colonna
Journal: Nature Immunology (2022)
Sphingolipids and metabolic disease: Will the real killer please stand up?
Authors: Thorsten Hornemann
Journal: Molecular Therapy (2022)

Sphingolipids (SLs) are essential constituents of cell membranes and important signaling molecules. Clinical studies showed, that sphingolipids, and in particular ceramides, are associated with metabolic diseases such as type 2 diabetes mellitus, hepatic steatosis, and coronary heart disease. This has been recapitulated in cell and animal models, demonstrating that increased ceramide levels promote hepatic steatosis, insulin resistance, β cell dysfunction, and apoptosis.1 In this issue, Schmidt and colleagues describe a therapeutic approach employing anti-sense oligonucleotides (ASOs) to reduce ceramide synthase 2 (CerS2) expression in mice.
A DEEP LEARNING MODEL FOR INFERRING ELEVATED PULMONARY CAPILLARY WEDGE PRESSURES FROM THE 12-LEAD ELECTROCARDIOGRAM
Authors: Daphne Schlesinger, Nathaniel Diamant, Aniruddh Raghu, Erik Reinertsen, Katherine Young, Puneet Batra, Eugene V. Pomerantsev, Collin Stultz
Journal: Journal of the American College of Cardiology (2022)
THE UTILITY OF D-DIMERS TO RULE OUT LEFT ATRIAL APPENDAGE THROMBUS: A META-ANALYSIS
Authors: Charbel Noujaim, Mario Njeim, Mario Mekhael, Abdel Hadi El Hajjar, Yichi Zhang, Christopher Pottle, Lilas Dagher, Ghassan Sleilaty, Chao Huang, Chan Ho Lim, Tarek Hassan Ayoub, Nassir F. Marrouche
Journal: Journal of the American College of Cardiology (2022)
Tempo of Degeneration Across Independently Evolved Nonrecombining Regions
Authors: Fantin Carpentier, Ricardo C. Rodríguez de la Vega, Paul Jay, Marine Duhamel, Jacqui A. Shykoff, Michael H. Perlin, R. Margaret Wallen, Michael E. Hood, Tatiana Giraud
Journal: Molecular Biology and Evolution (2022)

Recombination is beneficial over the long term, allowing more effective selection. Despite long-term advantages of recombination, local recombination suppression can evolve and lead to genomic degeneration, in particular on sex chromosomes. Here, we investigated the tempo of degeneration in nonrecombining regions, that is, the function curve for the accumulation of deleterious mutations over time, leveraging on 22 independent events of recombination suppression identified on mating-type chromosomes of anther-smut fungi, including newly identified ones. Using previously available and newly generated high-quality genome assemblies of alternative mating types of 13 Microbotryum species, we estimated degeneration levels in terms of accumulation of nonoptimal codons and nonsynonymous substitutions in nonrecombining regions. We found a reduced frequency of optimal codons in the nonrecombining regions compared with autosomes, that was not due to less frequent GC-biased gene conversion or lower ancestral expression levels compared with recombining regions. The frequency of optimal codons rapidly decreased following recombination suppression and reached an asymptote after ca. 3 Ma. The strength of purifying selection remained virtually constant at dN/dS = 0.55, that is, at an intermediate level between purifying selection and neutral evolution. Accordingly, nonsynonymous differences between mating-type chromosomes increased linearly with stratum age, at a rate of 0.015 per My. We thus develop a method for disentangling effects of reduced selection efficacy from GC-biased gene conversion in the evolution of codon usage and we quantify the tempo of degeneration in nonrecombining regions, which is important for our knowledge on genomic evolution and on the maintenance of regions without recombination.
Evaluating the Effectiveness of Diagnostic Tests
Authors: Ashley Graham Kennedy
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal